GlaxoSmithKline has made innovation its top priority as the drugmaker seeks to land federal approval of six drugs within the next 12 months, CEO Emma Walmsley told CNBC this week. Performance and trust round out the balance of GSK’s main priorities in 2020 as the British company labors to make advancements in treatments for a number of diseases, Walmsley said in a “Mad Money” interview from J.P. Morgan’s annual health-care conference in San Francisco. Walmsley, however, stopped short of saying how much GSK would spend on the research and development. She said the company is “accelerating investment,” but one of its “biggest cultural transformations” is in taking a more disciplined approach. Learn More